Xbrane Biopharma AB

OSTO:XBRANE (Sweden)  
kr 0.30 (+11.54%) Mar 28
At Loss
P/B:
0.23
Market Cap:
kr 79.28M ($ 7.41M)
Enterprise V:
kr 153.40M ($ 14.33M)
Volume:
42.91M
Avg Vol (2M):
8.57M
Also Trade In:
Volume:
42.91M
At Loss
Avg Vol (2M):
8.57M

Business Description

Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.69
Equity-to-Asset 0.37
Debt-to-Equity 0.73
Debt-to-EBITDA -0.83
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.05
Distress
Grey
Safe
Beneish M-Score 2.17
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 26.82
9-Day RSI 35.06
14-Day RSI 39.93
6-1 Month Momentum % -79.06
12-1 Month Momentum % -92.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.75
Quick Ratio 1.41
Cash Ratio 0.43
Days Inventory 215.93
Days Sales Outstanding 5.42
Days Payable 85.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.3
Shareholder Yield % -167.82

Financials (Next Earnings Date:2024-05-16)

OSTO:XBRANE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Xbrane Biopharma AB Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 189.103
EPS (TTM) (kr) -1.181
Beta 2.4
Volatility % 361.65
14-Day RSI 39.93
14-Day ATR (kr) 0.293809
20-Day SMA (kr) 0.82655
12-1 Month Momentum % -92.77
52-Week Range (kr) 0.134906 - 11.812816
Shares Outstanding (Mil) 262.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Xbrane Biopharma AB Filings

Filing Date Document Date Form
No Filing Data

Xbrane Biopharma AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Xbrane Biopharma AB Frequently Asked Questions

What is Xbrane Biopharma AB(OSTO:XBRANE)'s stock price today?
The current price of OSTO:XBRANE is kr0.30. The 52 week high of OSTO:XBRANE is kr11.81 and 52 week low is kr0.13.
When is next earnings date of Xbrane Biopharma AB(OSTO:XBRANE)?
The next earnings date of Xbrane Biopharma AB(OSTO:XBRANE) is 2024-05-16.
Does Xbrane Biopharma AB(OSTO:XBRANE) pay dividends? If so, how much?
Xbrane Biopharma AB(OSTO:XBRANE) does not pay dividend.

Press Release

Subject Date
No Press Release